Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Loomba

Showing results (81-90 of 748) with videos related to

Pageof 75
Sort By:
The Journal of Clinical Investigation|July 1, 2025
Therapeutic horizons in metabolic dysfunction-associated steatohepatitisPhilip N Newsome, Rohit Loomba
Annals of Gastroenterology|May 23, 2022
Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosisEmmanouil Sinakos, Christina Liava, Rohit Loomba
Alimentary Pharmacology & Therapeutics|December 28, 2023
Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver diseaseRohit Loomba, Vincent Wai-Sun Wong
Mayo Clinic Proceedings|May 7, 2016
In Reply-Diet and Activity Programs Are Ineffective in Nonalcoholic Fatty Liver DiseaseErin K J Spengler, Rohit Loomba
Expert Opinion on Emerging Drugs|August 9, 2016
Promising therapies for treatment of nonalcoholic steatohepatitisMazen Noureddin, Alice Zhang, Rohit Loomba
Clinical and Molecular Hepatology|December 30, 2024
Current Burden of MASLD, MetALD, and Hepatic Fibrosis among US Adults with Prediabetes and Diabetes, 2017-2023Donghee Kim, Rohit Loomba, Aijaz Ahmed
Current Diabetes Reports|March 20, 2021
The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular RiskCyrielle Caussy, Adrien Aubin, Rohit Loomba
The New England Journal of Medicine|December 6, 2023
Randomized Trial of Pegozafermin in NASH. ReplyRohit Loomba, Hank Mansbach, Maya Margalit
The Lancet. Gastroenterology & Hepatology|November 30, 2025
Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitisWenhao Li, William Alazawi, Rohit Loomba
Liver International : Official Journal of the International Association for the Study of the Liver|November 28, 2024
Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and CirrhosisDaniel Lindén, Gregory Tesz, Rohit Loomba
Pageof 75

Showing results (81-90 of 748) with videos related to

Sort By:
Pageof 75
The Journal of Clinical Investigation|July 1, 2025
Therapeutic horizons in metabolic dysfunction-associated steatohepatitisPhilip N Newsome, Rohit Loomba
Annals of Gastroenterology|May 23, 2022
Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosisEmmanouil Sinakos, Christina Liava, Rohit Loomba
Alimentary Pharmacology & Therapeutics|December 28, 2023
Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver diseaseRohit Loomba, Vincent Wai-Sun Wong
Mayo Clinic Proceedings|May 7, 2016
In Reply-Diet and Activity Programs Are Ineffective in Nonalcoholic Fatty Liver DiseaseErin K J Spengler, Rohit Loomba
Expert Opinion on Emerging Drugs|August 9, 2016
Promising therapies for treatment of nonalcoholic steatohepatitisMazen Noureddin, Alice Zhang, Rohit Loomba
Clinical and Molecular Hepatology|December 30, 2024
Current Burden of MASLD, MetALD, and Hepatic Fibrosis among US Adults with Prediabetes and Diabetes, 2017-2023Donghee Kim, Rohit Loomba, Aijaz Ahmed
Current Diabetes Reports|March 20, 2021
The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular RiskCyrielle Caussy, Adrien Aubin, Rohit Loomba
The New England Journal of Medicine|December 6, 2023
Randomized Trial of Pegozafermin in NASH. ReplyRohit Loomba, Hank Mansbach, Maya Margalit
The Lancet. Gastroenterology & Hepatology|November 30, 2025
Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitisWenhao Li, William Alazawi, Rohit Loomba
Liver International : Official Journal of the International Association for the Study of the Liver|November 28, 2024
Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and CirrhosisDaniel Lindén, Gregory Tesz, Rohit Loomba
Pageof 75